Pharmaceuticals

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are

30 November 2025

Novo Nordisk Stock Today, 28 November 2025: Goldman Sachs Trims Target as Obesity Pipeline Fights Back

Novo Nordisk (NYSE: NVO) shares are trying to stabilise after a bruising November as fresh obesity‑drug data, a higher‑dose Wegovy filing and new analyst calls collide with lingering worries about growth and competition. 1. How Novo Nordisk stock is trading

28 November 2025

Analyst Ratings · Investment News · NYSE:NVO · Obesity Treatments · Pharma Industry · Stock Market

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc (LON:GSK; NYSE:GSK) is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to

28 November 2025

Company News · Financial Trends · Investment Analysis · NYSE:GSK · Pharmaceuticals · Stock Market

Bayer Aktie (BAYN) Soars Over 10% on Stroke Drug Breakthrough – All Key News for 24 November 2025

Bayer’s share price is having its strongest single session in a long time. On Monday, 24 November 2025, the Bayer Aktie (BAYN) on Xetra jumped roughly 9–11% to trade around €30–31, briefly touching a new year high near €31 and

24 November 2025

Bayer · Investing · Market Analysis · Pharma News · Stocks

DAX Today: German Stock Market Rebounds as Bayer Soars on Stroke-Drug Success — 24 November 2025

Germany’s stock market started the new week with a relief rally on Monday, 24 November 2025. The DAX 40 clawed back part of last week’s heavy losses as investors cheered a double‑digit surge in Bayer shares and looked past another weak reading on German

24 November 2025

DAX · Financial Markets · German Stocks · Market Recovery · NYSE:BAYRY · Pharmaceutical News

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Published November 24, 2025 Eli Lilly has done something no other health‑care company has ever achieved: it has joined the $1 trillion market‑capitalization club, a group previously dominated almost entirely by technology giants like Apple, Microsoft and Nvidia. After briefly

24 November 2025

Business News · Pharmaceuticals · Stock Market · Technology · Weight Loss

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. (NYSE: MRK) is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of

22 November 2025

Company Updates · Dividends · Investment News · Pharmaceuticals · Stock Market

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO)

21 November 2025

Financial Analysis · Healthcare Industry · Investment News · NYSE:NVO · Pharmaceuticals · Stock Market

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock (NYSE: PFE) is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed

13 November 2025

Dividends · Healthcare Investments · Mergers & Acquisitions · NASDAQ:BNTX · NYSE:PFE · Pharmaceuticals · Stock Analysis

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs

11 November 2025

Business News · Mergers & Acquisitions · NYSE:MRK · NYSE:NVO · NYSE:PFE · Oncology · Pharmaceuticals · Stock Market

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board

10 November 2025

Healthcare Industry · Market Analysis · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Pharmaceutical Stocks · Stock Updates

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0

6 November 2025

COVID-19 · Earnings · Market News · NASDAQ:MRNA · Pharmaceuticals · Stocks